Anvisa board appointment highlights Brazilian hot topics
This article was originally published in Clinica
Jaime César de Moura Oliveira has joined the four-member directorship of Brazil’s healthcare regulatory agency, Anvisa. Mr Oliveira enters the agency with a background that includes ministerial legal support roles and his areas of expertise are bioethics, biosecurity and environmental law. His appointment was approved by the Senate’s social affairs committee during a meeting to discuss the regulatory themes he was most interested in. The themes included: the importance of cultivating the agency’s public consultations process as the means of ensuring the best adoption of Anvisa’s policies and guidance; and the war on clandestine and counterfeit healthcare products.
You may also be interested in...
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.
VMS businesses are deemed essential in Department of Homeland Security guidance that provides as basis for orders by most states and localities across the US. During an AHPA webinar, attorney Trent Norris says the federal government prefers leaving business exemptions to shut-down decisions to the states.
Company expects clinical trials to begin by September and says first batches could be available for emergency use authorization in early 2021; J&J pledges vaccine will be available to public on not-for-profit basis.